Literature DB >> 33611799

The involvement of semaphorin 7A in tumorigenic and immunoinflammatory regulation.

Yao Song1, Liu Wang1, Lan Zhang1,2, Dingming Huang1,2.   

Abstract

Semaphorins, a large group of highly conserved proteins, consist of eight subfamilies that are widely expressed in vertebrates, invertebrates, and viruses and exist in membrane-bound or secreted forms. First described as axon guidance cues during neurogenesis, semaphorins also perform physiological functions in other organ systems, such as bone homeostasis, immune response, and tumor progression. Semaphorin 7A (SEMA7A), also known as CDw108, is an immune semaphorin that modulates diverse immunoinflammatory processes, including immune cell interactions, inflammatory infiltration, and cytokine production. In addition, SEMA7A regulates the proliferation, migration, invasion, lymph formation, and angiogenesis of multiple types of tumor cells, and these effects are mediated by the interaction of SEMA7A with two specific receptors, PLXNC1 and integrins. Thus, SEMA7A is intimately related to the pathogenesis of multiple autoimmune and inflammation-related diseases and tumors. This review focuses on the role of SEMA7A in the pathogenesis of autoimmune disorders, inflammatory diseases, and tumors, as well as the underlying mechanisms. Furthermore, strategies targeting SEMA7A as a potential predictive, diagnostic, and therapeutic agent for these diseases are also addressed.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  autoimmune diseases; inflammatory diseases; semaphorin 7A; therapeutic target; tumor

Year:  2021        PMID: 33611799     DOI: 10.1002/jcp.30340

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis.

Authors:  Qiong Pan; Gang Luo; Jiaquan Qu; Sheng Chen; Xiaoxun Zhang; Nan Zhao; Jingjing Ding; Hong Yang; Mingqiao Li; Ling Li; Ying Cheng; Xuan Li; Qiaoling Xie; Qiao Li; Xueqian Zhou; Huiling Zou; Shijun Fan; Lingyun Zou; Wei Liu; Guohong Deng; Shi-Ying Cai; James L Boyer; Jin Chai
Journal:  EMBO Mol Med       Date:  2021-09-29       Impact factor: 12.137

2.  A Comprehensive Prognostic Analysis of Tumor-Related Blood Group Antigens in Pan-Cancers Suggests That SEMA7A as a Novel Biomarker in Kidney Renal Clear Cell Carcinoma.

Authors:  Yange Wang; Chenyang Li; Xinlei Qi; Yafei Yao; Lu Zhang; Guosen Zhang; Longxiang Xie; Qiang Wang; Wan Zhu; Xiangqian Guo
Journal:  Int J Mol Sci       Date:  2022-08-08       Impact factor: 6.208

3.  SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface.

Authors:  Nan Zhao; Xiaoxun Zhang; Jingjing Ding; Qiong Pan; Ming-Hua Zheng; Wen-Yue Liu; Gang Luo; Jiaquan Qu; Mingqiao Li; Ling Li; Ying Cheng; Ying Peng; Qiaoling Xie; Qinglin Wei; Qiao Li; Lingyun Zou; Xinshou Ouyang; Shi-Ying Cai; James L Boyer; Jin Chai
Journal:  JCI Insight       Date:  2022-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.